# Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

> **NCT00003368** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Lymphoma
- Small Intestine Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003368
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-06
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** — (—)
- **Last updated:** 2013-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003368, "Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00003368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*